High-Throughput and Cost-Effective Characterization of Induced Pluripotent Stem Cells

• DOI: 10.1016/j.stemcr.2017.03.011
• Publication Date: 2017-04-07T02:37:41Z
• Authors: Matteo D'Antonio; Grace Woodruff; Jason L. Nathanson; Agnieszka D'Anton...; Angelo Arias; Hiroko Matsui; Roy Williams; Cheryl Herrera; Sol M. Reyna; Gene W. Yeo; Lawrence S.B. Gol...; Athanasia D. Pano...; Kelly A. Frazer
• Keywords: Resource; 570; Medicine (General); Genotype; induced pluripotent stem cells; QH301-705.5; 1.1 Normal biological development and functioning; Cost-Benefit Analysis; Clinical Sciences; Induced Pluripotent Stem Cells; Regenerative Medicine; 576; high-throughput methods; Cell Line; 03 medical and health sciences; R5-920; Genetics; 2.1 Biological and endogenous factors; fluorescent cell barcoding; Humans; Myocytes, Cardiac; Biology (General); pluripotency characterization; Neurons; Myocytes; 0303 health sciences; SNP arrays; Stem Cell Research - Induced Pluripotent Stem Cell - Human; Stem Cell Research - Induced Pluripotent Stem Cell; flow cytometry; Genetic Variation; Cell Differentiation; Biological Sciences; Stem Cell Research; Cellular Reprogramming; digital karyotyping; High-Throughput Screening Assays; 3. Good health; differentiation potential; qPCR; Phenotype; Biochemistry and cell biology; Karyotyping; Generic health relevance; Biochemistry and Cell Biology; Cardiac; Biomarkers

Highlights•Combining three high-throughput methods provides low-cost characterization of iPSCs•iPSC line heterogeneity is assessed by fluorescent cell barcoding flow cytometry•12-gene qPCR enables gene expression analysis in vitro differentiation potential•SNP arrays provide inexpensive high-resolution digital karyotypingSummaryReprogramming somatic cells to induced pluripotent stem (iPSCs) offers the possibility studying molecular mechanisms underlying human diseases types difficult extract from living patients, such as neurons and cardiomyocytes. To date, studies have been published that use small panels iPSC-derived lines study monogenic diseases. However, complex diseases, where genetic variation disorder unknown, a sizable number patient-specific iPSC controls need be generated. Currently for deriving characterizing iPSCs are time consuming, expensive, and, some cases, descriptive but not quantitative. Here we set out develop simple reduce cost increase throughput lines. Specifically, outline quantification surface markers, potential, evaluation karyotype with markedly reduced cost.Graphical abstract